References
- Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086–97.
- Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci 1996;93:15051–6.
- Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109:9629–34.
- Schneider F, Hammarström P, Kelly JW. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 2001;10:1606–13.
- Sant'Anna R, Gallego P, Robinson LZ, Pereira-Henriques A, Ferreira N, Pinheiro F, Reixach N, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 2009;7:10787
- Molina DM, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, Nordlund P, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013;341:84–7.
- Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman RL, Kelly JW, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry 2014;53:1993–2006.
- Lundberg E, Olofsson A, Westermark GT, Sauer-Eriksson AE. Stability and fibril formation properties of human and fish transthyretin, and of the Escherichia coli transthyretin-related protein. Febs J 2009;276:1999–2011.